Culmerciclib maleate

• CAT Number: I041313
• CAS Number: 2197922-55-5
• Molecular Formula: C28H31FN8O4
• Molecular Weight: 562.60
• Purity: ≥95%
• Synonyms: (Z)-but-2-enedioic acid;5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)-N-(5-piperazin-1-ylpyridin-2-yl)pyrimidin-2-amine
• InChI: InChI=1S/C24H27FN8.C4H4O4/c1-15(2)23-18-12-16(4-6-20(18)31-32(23)3)22-19(25)14-28-24(30-22)29-21-7-5-17(13-27-21)33-10-8-26-9-11-33;5-3(6)1-2-4(7)8/h4-7,12-15,26H,8-11H2,1-3H3,(H,27,28,29,30);1-2H,(H,5,6)(H,7,8)/b;2-1-
• InChIKey: WDTNPNAGOVXTGJ-BTJKTKAUSA-N
• SMILES: CC(C)C1=C2C=C(C=CC2=NN1C)C3=NC(=NC=C3F)NC4=NC=C(C=C4)N5CCNCC5.C(=C\C(=O)O)\C(=O)O

Culmerciclib maleate（Cat No.:I041313）is an investigational small molecule inhibitor being developed for the treatment of cancer. It targets and inhibits cyclin-dependent kinases (CDKs), particularly CDK9, which plays a critical role in regulating transcription and cell cycle progression. By blocking CDK9, Culmerciclib maleate disrupts cancer cell proliferation and survival, inducing apoptosis and potentially sensitizing tumors to other cancer therapies. Preclinical studies suggest that it may be effective in treating various cancers, including those resistant to traditional therapies, offering a promising targeted treatment approach with potentially fewer side effects.